Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2306-2310

  Jones Jr , D V ^a   Lozano, R ^a   Hoque, A ^a   Markowitz, A ^a   Patt, Y Z ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; LOMUSTINE; PACLITAXEL;

ADULT; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GALLBLADDER CARCINOMA; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 10144247898     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2306     Document Type: Article

References (35)

1. Wanebo HJ, Ahlgren JD, Hill MC: Cancer of the biliary tract, in Ahlgren JD, Macdonald JS (eds): Gastrointestinal Oncology. Philadelphia, PA, Lippincott 1992, pp 399-416
2. Ahlgren JD: Neoplasms of the hepatobiliary system, in Calabresi P, Schein PS (eds): Medical Oncology (ed 2). New York, NY, McGraw-Hill, 1993, pp 713-739
3. Frierson HF, Fechner RE: Pathology of malignant neoplasms of the gallbladder and extrahepatic bile ducts, in Wanebo HJ (ed): Hepatic and Biliary Cancer. New York, NY, Dekker, 1987, pp 281-297
4. Hamrick RE Jr, Liner FJ, Hastings PR, et al: Primary carcinoma of the gallbladder. Ann Surg 195:270-273, 1982
5. Roberts JW, Daugherty SF: Primary carcinoma of the gallbladder. Surg Clin North Am 66:743-749, 1986
6. Wanebo HJ, Castle WN, Fechner RE: Is carcinoma of the gallbladder a curable lesion? Ann Surg 195:624-631, 1982
7. Bedikian M, Valdivieso M, DeLaCrus A, et al: Cancer of the extrahepatic bile ducts. Med Pediatr Oncol 8:53-61, 1980
8. Evander A, Fredlund P, Hoevels J, et al: Evaluation of aggressive surgery for carcinoma of the extrahepatic bile ducts. Ann Surg 191:23-29, 1980
9. Pitt HA, Roslyn JJ, Tompkins RK: Surgical resection of bile duct cancer, in Wanebo HJ (ed): Hepatic and Biliary Cancer. New York, NY, Dekker, 1987, pp 339-355
10. Davis HL, Ramirez G, Ansfield FJ: Adenocarcinoma of the stomach, pancreas, liver, and biliary tracts: Survival of 328 patients treated with fluoropyrimidine therapy. Cancer 33:193-197, 1974
11. Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperative gallbladder and bile duct cancer. Cancer 54:965-969, 1984
12. Haskell CM. Cancer of the liver, in Haskell CM (ed): Cancer Treatment. Philadelphia, PA, Saunders, 1980, pp 319-324
13. Schiff PB, Fant J, Horowitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 22:665-667, 1979
14. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1778-1781, 1991
15. McGuire WP, Rowinsky EK, Rosenheim NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
16. Ajani JA, Ilson D, Daugherty K, et al: Paclitaxel (Taxol) is active against carcinoma of the esophagus: Report of a phase II trial. Proc Am Soc Clin Oncol 13:192, 1994 (abstr 555)
17. Thornton D, Singh K, Putz B, et al: A phase II trial of Taxol in squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 13:288, 1994 (abstr 933)
18. Roth BJ, Dreicer R, Einhorn LH, et al: Paclitaxel in previously untreated, advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Proc Am Soc Clin Oncol 13:230, 1994 (abstr 704)
19. Younes A, Sarris A, McLaughlin P, et al: Phase II trial of Taxol given as a 3-hour infusion every 3 weeks in relapsed non-Hodgkins lymphoma (NHL). Proc Am Soc Clin Oncol 13:374, 1994 (abstr 1267)
20. Simon R: Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 10:1-10, 1989
21. Crooke ST, Bradner WT: Mitomycin C: A review. Cancer Treat Rev 3:121-139, 1976
22. von Eyben F, Hellekant C, Mattson M, et al: Mitomycin-C in advanced gallbladder carcinoma. Acta Radiol Oncol 19:81-84, 1980
23. Harvey JH, Smith FP, Schein PS: 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 2:1245-1248, 1984
24. Hall SW, Benjamin RS, Murphy WK, et al: Adriamycin, BCNU, ftorafur chemotherapy of pancreatic and biliary tract cancer. Cancer 44:2008-2013, 1979
25. Zarba J, Rougier P, Armand JP, et al: Cisplatin (P) and 5 day continuous infusion (CI) of 5FU in treatment of metastatic biliary tract cancer: A phase II trial. Proc Am Assoc Cancer Res 33:1297A, 1992 (abstr)
26. Sali A, McQuillan T, Read A, et al: Rifampicin as cytotoxic agent for cholangiocarcinoma: Preliminary report of seven cases. J Cancer Res Clin Oncot 117:503-504, 1991
27. Brown T, Tangen C, Fleming T, et al: A phase II trial of Taxol and granulocyte colony-stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. Proc Am Soc Clin Oncol 12:200, 1993 (abstr 592)
28. Einzig AI, Wiernik PH, Lipsitz AB, et al: Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: The Eastern Cooperative Oncology Group results. Proc Am Soc Clin Oncol 12:194, 1993 (abstr 566)
29. Ajani JA, Ilson DH, Kelsen DP. The activity of paclitaxel in gastrointestinal tumors. Semin Oncol 22:46-50, 1995
30. Sulkes A, Smyth J, Sessa C, et al: Docetaxel) Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380-383, 1994
31. Hainsworth JD, Thompson DS, Greco FA, Paclitaxel by 1-hour infusion: An active drug in metastic non-small-cell lung cancer. J Clin Oncol 13:1609-1614, 1995
32. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and schedule issues in the development of paclitaxel (TAXOL). Semin Oncol 20:31-39, 1993 (suppl 4)
33. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
34. Chang AY, Boros L, Garrow G, et al: Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease. Semin Oncol 22:124-127, 1995 (suppl 6)
35. Eisenhauer EA, Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994